业绩方面，汉诺医疗呈现典型的"增收不增利"特征。据招股书数据，2022年公司营业收入为0，主要因 核心产品尚未实现商业化销售；2023年实现营收2983.11万元，2024年增至4930.88万元，2025年上半年 已达3735.53万元，近年营收稳步增长。但净利润端持续承压，公司在2022年至2024年的净利润分别 为-6478.83万元、-3.41亿元、-1.83亿元，累计亏损规模庞大；2025年上半年亏损有所收窄，至8227.32万 元。 这一局面与ECMO行业特性及公司业务结构密切相关。作为高端医疗设备，ECMO研发周期长、资金需 求大、技术迭代快，因此汉诺医疗需维持高额研发投入以筑牢壁垒。招股书显示，2022年至2024年公司 累计研发投入超3.8亿元，2025年上半年研发投入近5200万元。其人员结构也印证了技术密集属性：截 至2024年末，公司员工总数194人，其中研发人员70人，占比超30%——不仅符合高技术企业特征，更 远超科创板对研发人员占比不低于10%的基础要求。但公司短板同样明显，目前其营收几乎全部依赖 ECMO系统，ECPR、CPS等衍生产品仍处于商业化初期，尚未贡献收入，也就是说， ...

Core Viewpoint - Yinuo Kang Medical Technology (Suzhou) Co., Ltd. is progressing with its initial public offering (IPO) guidance, with Huatai United Securities as the advisory institution, focusing on fundraising project preparations and feasibility assessments [2][4] Group 1: Company Overview - Yinuo Kang was established in 2014 and specializes in the research, production, sales, and service of high-end ultrasound and ophthalmic surgical instruments [4] - The company is headquartered in the Suzhou area of the China (Jiangsu) Pilot Free Trade Zone and has a production base and some R&D collaboration projects in Hefei, as well as a research center in California, USA [4] - Yinuo Kang has developed core technologies in high-end medical devices, including ultrasound energy platforms, electrosurgical energy platforms, ophthalmic instruments, and minimally invasive surgical robots, with a focus on surgical instrument systems and high-value consumables [4] Group 2: Intellectual Property and Shareholding - The company has applied for 245 domestic patents and 52 international patents to protect its innovations [4] - The controlling shareholder is Liu Shougong, who directly holds 38.98% of the shares, while Liu Shougong and Luo Wei together control 65.87% of the company [4] - Liu Shougong serves as the chairman, and Luo Wei is the manager and director of the company [4] Group 3: IPO Guidance Progress - The IPO guidance work began in August 2025 and is currently being reported for the period from August to September 2025 [2] - The guidance team, led by Sun Shenghu, includes members Wang Zhaoqian, Lian Ke, Tang Chengwei, and Pang Zhiyuan [2] - The team is focusing on the company's operational status and future development strategies, urging the company to prepare for fundraising projects and assess their feasibility and necessity [2]

Core Viewpoint - Midea Group's medical subsidiary, Beijing Wandong Medical Technology Co., Ltd., has successfully passed expert acceptance for the "National New Material Production Application Demonstration Platform - Medical Device Material Production Application Demonstration Platform" project, marking a significant advancement in China's high-end medical equipment sector [1] Group 1 - The platform focuses on key material research and whole machine application transformation, achieving breakthroughs in multiple technical bottlenecks [1] - This initiative represents a major leap for China in high-performance medical equipment, transitioning from a follower to a leader in the field [1] - The platform was established by Wandong Medical in collaboration with 13 upstream and downstream units in the industry chain, creating an integrated innovation system encompassing "materials-components-whole machine-verification" [1] Group 2 - Over three years of construction, the platform has successfully developed six types of key materials, overcome six core component challenges, and produced six types of high-end medical equipment [1] - The most notable achievement is the successful development of the world's first liquid helium-free superconducting magnetic resonance imaging (MRI) system [1]

Core Viewpoint - Inokang Medical Technology (Suzhou) Co., Ltd. has initiated the listing guidance process with Huatai Securities, marking a significant step towards its public offering in the high-end medical device sector [1][2] Company Overview - Inokang was founded in 2014 by a team of overseas returnees and experienced professionals in the domestic medical industry, headquartered in Suzhou, Jiangsu, with production bases in Hefei and a research center in California, USA [1] - The company focuses on high-end medical devices, including ultrasound energy platforms, electrosurgical energy platforms, ophthalmic instruments, and minimally invasive surgical robots, emphasizing core technology innovation and intellectual property protection [1] Technological Platforms - Inokang concentrates on three main technology platforms: - Ultrasound energy platform for soft tissue cutting and hemostasis devices - Electrosurgical energy platform for minimally invasive surgery - Ophthalmic instruments and surgical robots, including cataract ultrasound emulsification systems, with products certified for international medical device standards [1][2] Market Achievements - The company has received the national-level "specialized and innovative small giant" enterprise title and has obtained multiple important medical device registrations domestically and internationally, with its ultrasound knife series products sold in over 70 countries and regions [2] - Inokang's products have achieved significant international certifications, including the Korean integrated ultrasound knife head registration certificate and the European MDRCE7MM certificate [2] Shareholding Structure - The controlling shareholder of Inokang is Liu Shougong, who directly holds 38.98% of the company's shares, while the actual controllers, Liu Shougong and Luo Wei, collectively control 65.87% of the company [2]

报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月11日，NMPA官网显示，国家药品监督管理局批准了 上海汇禾医疗科技股份有限公司 的 "经导管三尖瓣环成形系统" 创新产品注册申请。 合作伙伴征集：2025全球手术机器人大会 # 关于K-Clip ® 经导管三尖瓣环修复系统 据企业官方信息，K-Clip ® 是全球首创的经导管三尖瓣环修复系统，通过微创手术方式，复刻了经典的外科Kay's手术，将扩大的三尖瓣环折叠环缩，从而修复三 尖瓣反流。手术创伤小，恢复快，手术时间平均约30分钟。 图片源自公司官方公众号（下同） 研发历程 2018年6月，汇禾医疗从红酒开瓶器中获得灵感，设计了K-Clip ® 。该产品历经100多次迭代、2500余次测试、5000多张设计图纸，最终通过了380多头活体大 动物的验证。 临床研究： 2021年4月，复旦大学附属中山医院葛均波院士团队完成了K-Clip ® 的首例人体植入。 2021年10月，K-Clip ® 进入国家药品监督管理局（NMPA）创新医疗器械特别审批"绿色通道"。 2022 ...